Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?
2/5 보강
TL;DR
Biomarkers integrating blood counts and flow cytometry may predict CMML prognosis irrespective of treatment and both higher absolute cMo and iGRAN counts independently predicted poorer OS, without significant interaction with treatment arm.
OpenAlex 토픽 ·
Acute Myeloid Leukemia Research
Myeloproliferative Neoplasms: Diagnosis and Treatment
Immune cells in cancer
Biomarkers integrating blood counts and flow cytometry may predict CMML prognosis irrespective of treatment and both higher absolute cMo and iGRAN counts independently predicted poorer OS, without sig
- 표본수 (n) 63
- p-value p = 0.0003
- p-value p = 0.013
- HR 5.38
APA
Dorothée Selimoglu-Buet, Sylvie Chevret, et al. (2026). Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?. Leukemia, 40(4), 806-815. https://doi.org/10.1038/s41375-026-02901-w
MLA
Dorothée Selimoglu-Buet, et al.. "Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?." Leukemia, vol. 40, no. 4, 2026, pp. 806-815.
PMID
41803403 ↗
Abstract 한글 요약
Whether mitigation of myeloproliferation improves prognosis of CMML independently of bone marrow response is unknown. Flow-defined classical monocytes (cMo) and immature granulocytes (iGRAN) have not yet been studied as biomarkers of response. We inspected the prognostic value of WBC, circulating monocytes, cMo and iGRANs in the 120 DACOTA (NCT02214407) patients randomized to decitabine (n = 63) or hydroxyurea (n = 57) evaluated after 3 cycles with BM aspiration and complete blood count. Across arms, 59% and 56% patients had monocytes > 1 × 10/L or WBC > 10 × 10/L at the 3- and 6-cycle evaluation respectively. After 6 cycles, persistence of monocytes > 1 × 10/L or WBC > 10 × 10/L increased the hazard of death (HR = 5.38, p = 0.0003) irrespective of treatment, baseline CPSS and persistence of BM blast excess. After 3 cycles, both higher absolute cMo and iGRAN counts independently predicted poorer OS, without significant interaction with treatment arm. Median OS from landmark was 35.1 months in the 28% patients with cMo ≤ 0.94 ×10/L AND iGRAN ≤ 0.40 ×10/L versus 15.3 months in others (p = 0.013). Biomarkers integrating blood counts and flow cytometry may predict CMML prognosis irrespective of treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.